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Abstract
Background: Drug resistance, a process mediated by multiple mechanisms, is a critical determinant for treating lung cancer.
The aim of this study is to determine if oleanolic acid (OA), a pentacyclic triterpene present in several plants, is able to
circumvent the mechanisms of drug resistance present in non-small cell lung cancer (NSCLC) cell lines and to induce their
death.
Principal Findings: OA decreased the cell viability of the NSCLC cell lines A459 and H460 despite the presence of active,
multidrug-resistant (MDR) MRP1/ABCC1 proteins and the anti-apoptotic proteins Bcl-2 and survivin. These effects are due to
apoptosis, as evidenced by the capacity of OA to induce fragmentation of DNA and activate caspase 3. Induction of NSCLC
cell death by OA cannot be explained by inhibition of the MDR proteins, since treatment with triterpene had little or no
effect on the activity or expression of MRP1. Moreover, treatment with OA had no effect on the expression of the anti-
apoptotic protein Bcl-2, but increased the expression of the pro-apoptotic protein Bax, altering the Bcl-2/Bax balance
towards a pro-apoptotic profile. OA also decreased the expression of the anti-apoptotic protein survivin. Furthermore, OA
decreased the expression of the angiogenic vascular endothelial growth factor (VEGF) and decreased the development of
melanoma-induced lung metastasis.
Conclusion: Our data provide a significant insight into the antitumoral and antimetastatic activity of OA in NSCLC and
suggest that including OA in the NSCLC regimens may help to decrease the number of relapses and reduce the
development of metastases.
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Introduction
Worldwide, lung cancer is the most frequent cause of cancer-
related death [1]. Non-small cell lung cancer (NSCLC) represents
over 80% of all diagnosed lung cancers. The high mortality of this
disease is attributable to the difficulties of early detection. At the
time of diagnosis, most patients have an unresectable, advanced
disease involving lymph-node or visceral metastasis, or both.
Platinum-based chemotherapy, one of the main treatments for
NSCLC in the last decades, exhibited several problems: in
addition to being very toxic, such chemotherapy only produced
a modest improvement in overall survival [2]. Even after the
development of drugs that target the growth of a tumor, the overall
survival rate of patients with NSCLC remained low [3]. The
chemotherapeutic failure in lung cancer may contribute to
metastasis and high morbidity, indicating that effective therapies
are needed.
Multidrug resistance (MDR) plays a critical role in the failure of
lung cancer chemotherapy. Although several mechanisms can
mediate MDR, researchers have devoted a great deal of attention
to the overexpression of transporter proteins of the adenosine 59-
triphosphate (ATP)-binding cassette (ABC) family and to alter-
ations of factors involved in the apoptotic process. Expression of
MDR proteins is considered the main cause of a patient’s relapse
after treatment; literature data [4,5] have described a relationship
between the expression of ABC proteins and the poor outcome of
NSCLC patients treated with chemotherapy. MDR proteins such
as P-glycoprotein (P-gp)/ABCB1 and Multiple Drug Resistant
Protein 1 (MRP1) work as efflux pumps that are capable of
removing a variety of drugs from the cell, thereby preventing cell
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pathways and/or amplify anti-apoptotic pathways are also
important factors in the development of chemotherapeutic
resistance in tumors [7,8]. Several studies showed that inhibiting
anti-apoptotic proteins of the B-cell lymphoma 2 (Bcl-2) [9,10] or
inhibitor of apoptosis (IAP) families [11,12] sensitizes NSCLC cells
to chemotherapy.
Another hallmark of malignant cancer cells is their ability to
establish metastasis. Since metastatic disease, rather than local
tumor growth, determines the mortality of patients, targeting
tumor metastasis has the highest priority in cancer therapy. A
substantial body of evidence has emerged suggesting that the axis
between the vascular endothelial growth factor (VEGF) receptor
and the Flk-1 kinase insert domain receptor (KDR) (VEGF-Flk-1/
KDR) is the dominant signal transduction pathway regulating
tumor angiogenesis and metastasis [13]. However, because the
main requirement for development of metastasis is the presence of
live tumor cells, mechanisms involved in drug resistance, such as
expression of MDR proteins and anti-apoptotic factors, have been
proposed as conditions favorable to development of metastasis
[14,15].
Many compounds of natural origin are capable of modulating
drug resistance. Oleanolic acid (OA), a pentacyclic triterpenoid
found in a variety of plant species, presents several biologic
properties, including anti-inflammatory [16,17], hepato- and
nefrotoxicity protection [18,19], recovery of the hematopoietic
system after irradiation [20] and cytotoxicity against several cancer
cell lines [21,22,23]. In a previous study, we showed that OA is
also effective against MDR erythroleukemic cells overexpressing
P-gp and its sensitive counterpart [24]. The present study was
performed to examine the cytotoxic effects of OA on NSCLC cells
(A549 and H460) that expressed both MRP1 [25,26] and anti-
apoptotic factors [7,8], and to investigate the effects of this
triterpene on pathways involved in drug resistance and the
development of metastasis.
OA induced apoptosis in both cell lines. Treatment with this
triterpene decreased the expression of survivin and increased the
expression of Bax, without affecting the expression of Bcl-2 or
MRP1. Moreover, OA decreased the expression of VEGF and
inhibited the development of melanoma-induced lung metastasis.
Together, these data suggest that OA may be a good candidate for
the treatment of tumors with intrinsic expression of resistance
mechanisms, such as lung tumors.
Materials and Methods
Materials
Oleanolic Acid (OA), molecular weight 456.7, provided by
Sigma Chemical Co. (Saint Louis, MO, USA), was dissolved to
10 mM of dimethyl sulfoxide (DMSO), stored at 220uC and
diluted in culture medium for use. DMSO, 3-(4,5 dimethylthiozol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), Propidium Iodide
(PI) and Rhodamine 123 (Rho123) were purchased from Sigma. 5-
carboxifluorescein diacetate (5-CFDA) was obtained from Calbio-
chem (San Diego, CA, USA). Dulbecco’s modified Eagle’s
medium (DMEM), fetal calf serum (FCS), penicillin and
streptomycin were from Life Technologies, Inc. (USA). FACS
lysing solution was from BD Biosciences (San Jose, CA). Caspases-
3 assay kit (CaspGlow) was from Biovision (Mountain View, CA,
USA). Antibodies against Bax (clone P-19), VEGF (clone C-1) and
tubulin (clone b-7) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Bcl-2 antibody (clone 124) was from
DAKO (Carpinteria, CA, USA) and survivin antibody (ab24479)
was purchased from ABCAM (Cambridge, MA, USA). Biotiny-
lated anti-mouse IgG and CY3-labeled streptavidin were from
Sigma. Biotinylated anti-goat IgG, anti-rabbit IgG and Vecta-
shieldH mounting medium were purchased from Vector Labora-
tories (Burlingame, CA, USA). 49,6-diamidino-2-phenylindole
(DAPI) and PE-labeled anti-MRP1 (QCRL-2) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-MRP1 (clone
A23, Axxora, San Diego, CA), Bcl-2 (clone bcl2-100, Zymed, San
Francisco, CA), anti-mouse HPR (Amersham, Arlington, IL) and
anti-rabbit HPR (GE Healthcare, Piscataway, NJ) were used for
the western blot.
Cells and Culture Conditions
The human non-small cell lung cancer cell lines A549 and
H460 and the murine melanoma line B16F10 were grown in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% heat-inactivated fetal calf serum (FCS), 100 U penicillin
and 100 mg/mL streptomycin in disposable plastic bottles at 37uC
with 5% CO2. Cells were sub-cultured using Trypsin-EDTA every
3–4 days.
Cell viability assay
Cell viability was assessed using the MTT assay. Briefly, 180 mL
of the lung cancer cell suspension (10
4/cells per well) was
distributed in 96-well plates and incubated for 24 h at 37uC/5%
CO2 to allow the culture to stabilize. The cells were then treated
with 20 mL of medium, various concentrations of OA (10, 25, 40
or 50 mg/mL or 21.9, 54.7, 87.6 or 109.5 mM, respectively);
DMSO concentrations for each dose were used as controls. After
48 h incubation, the culture was treated with 20 mL MTT (5 mg/
mL) and kept for 4 h at 37uC in the dark before being centrifuged
and the supernatant discarded. The formazan produced by
reduction of the MTT by viable cells was dissolved in DMSO
and the optical density was measured in an ELISA reader
(BenchMark, Bio-Rad, CA) at 570 nm (reference filter 630 nm).
Experiments were repeated at least three times. Results were
expressed as the mean 6 SD of percent inhibition of cell viability.
To check if high concentrations of OA would interfere with MTT
readings, OA were incubated with MTT in the same conditions
used for determination of cell viability. No interference was
observed.
DNA fragmentation assay
Apoptosis was assessed by cell cycle analysis using flow
cytometry. After 24 h resting, the plated lung cells (2610
4/well)
were treated with media or various concentrations of OA (10, 25,
and 50 mg/mL) and incubated for another 48 h. After this time,
cells were harvested, re-suspended in a hypotonic fluorescent
solution (50 mg/mL PI and 0.1% Triton X-100 in 0.1% Na
Citrate buffer) for 1 h, at 4uC in the dark. The cell cycle was
analyzed by flow cytometry (FL-2) (FACSCalibur, Becton
Dickinson, San Jose, CA) to determine the sub-G0/G1 DNA
content. Sub-diploid populations were considered to be apoptotic.
Data acquisition and analysis were controlled by Cellquest
software, version 3.1f. Each experiment was repeated at least
three times. The results were presented as representative
histograms and as mean 6 SD of the percentage of the DNA
that was fragmented.
Caspase activation assay
Caspase-3 activation was assayed using a commercial kit,
according to the instructions of the manufacturer (Biovision,
Mountain View, CA). In brief, cells plated as described in Cell
viability assay (M&M) were incubated for 48 h with medium
Oleanolic Acid in Cancer
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before being harvested, centrifuged, and suspended in caspase-3
assay solution. This assay solution contains a potent caspase
inhibitor conjugated to FITC that is cell permeable, non-toxic
and, irreversibly to activated caspase. After 1 h of incubation
(37uC, 5% CO2), cells were washed twice with washing buffer and
the percentage of caspase-3-activated cells was analyzed by flow
cytometry (FL-1). Results were presented as histograms represen-
tative of three different experiments.
Activity of MDR proteins
The activity of the MDR proteins was determined by the
accumulation of specific substrates. Rho123 and 5-carboxyfluor-
escein diacetate (CFDA), a non-fluorescent molecule that is
converted into the fluorescent carboxy-fluorescein (CF) by
intracellular esterases, were used to measure the activity of P-
gp/ABCB1 and MRP1/ABCC1, respectively [27,28].
For each experiment, the cells (1610
5/well) were seeded in 24
well plates and pre-incubated for 24 h at 37uC/5% CO2 to allow
the culture to stabilize. Cells were incubated for 30 min with
medium (autofluorescence); 400 nM Rho123 or 5 mM CFDA in
the presence of medium, inhibitors of P-gp (25 mM Verapamil) or
MRP1 (50 mM MK-571); or the desired concentrations of OA.
Then the cells were washed in PBS, harvested and kept on ice until
flow cytometry analysis (FACSCalibur, Beckton-Dickinson cytom-
eter). Results were presented as representative histograms or as the
mean 6 SD of arbitrary units of mean fluorescence intensity
(MIF).
Expression of MDR proteins
MRP1 expression was evaluated using flow cytometry and western
blot. Cells were plated and treated for 24 h with media or OA (either
25 or 50 mg/mL). For the flow cytometry, cells were harvested,
permeabilized with FACS lysing solution and incubated with PE-
labeled anti-MRP1(clone QCRL-2) for 30 minutes at 4uC.After two
PBS washings, cells were re-suspended in FACS solution and the
fluorescence evaluated. Results were presented as representative
histograms. For western blot, whole-cell extracts were prepared by
diluting the cell pellets directly in RIPA (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.5% Sodium deoxycholate, 0.1% SDS and 1%
protease inhibitor Kit (Amersham, Arlington, IL). Equal amounts of
protein were separated by SDS-PAGE and transferred to poly-
vinylidene difluoride (PDF) membranes. Blots were blocked for 2 h in
PBS/0.05%Tween containing 5% nonfat dried milk, probed with
specific antibodiesto MRP1(clone A23, 1:1000) or tubulin (clone b-7,
1:500) overnight and incubated with HPR-conjugated secondary
antibodies (1:2000 dilution; Amersham Biosciences, UK) for 1 hour
at room temperature. Blots were developed using the enhanced
chemiluminescence system (ECL, Amersham, Arlington, IL) accord-
ing to the manufacturer’s instructions. Band intensity was quantified
using the Scion Image Software and protein expression was
normalized in relation to a-tubulin.
Immunocytochemistry assays
A459 cells (3610
4/well) were seeded on cover slips in 24 well
plates, left to rest for 24 h and then treated with medium or
50 mg/mL OA. After 24 h incubation, the cells were washed twice
with phosphate saline buffer (PBS), pH 7.4, and fixed with a 4%
buffered paraformaldehyde solution containing 4% sucrose for
40 min at 4uC. After three washes in PBS, the cover slips were
incubated for 30 min in a 50 mM NH4Cl solution, pH 8.0, and
then washed again in PBS (3X). Nonspecific binding of
immunoglobulins was blocked for 60 min with a PBS solution
containing 5% BSA, 0.1% Triton X-100, 0.05% Tween 20 and
0.01% gelatin. The next step was to inhibit endogenous biotin
using a biotin blocking kit (Vector Lab.), according to the
manufacturer instructions.
After that, cells were incubated with a 1:50 dilution of a
monoclonal mouse anti-Bcl-2 antibody, 2 mg/mL polyclonal
rabbit anti-Bax antibody, 2 gu/mL mouse monoclonal anti-VEGF
antibody or 5 ug/mL survivin antibody, all diluted in PBS
containing 3% BSA and 0.05% Tween and maintained overnight
at 4uC in a humid chamber. Next, cells were washed in PBS
containing 0.25% Tween 20 and incubated for 1 h with 10 mg/
mL of the secondary antibody selected for that trial: biotinylated
anti-goat IgG, anti-rabbit IgG or anti-mouse IgG. After that step,
the coverslips were washed (3 times) with PBS/0.25% Tween and
incubated for 1 h at room temperature with 10 mg/mL strepta-
vidin conjugated to Cy3. Next, the coverslips were washed and
then stained with 0.5 mg/mL DAPI for 5 min. Following two
more washes, one with PBS and one in distilled water, the cover
slips were mounted with VectashieldH mounting medium and
observed by epi-fluorescence microscopy (Eclipse E-800, Nikon,
Japan). The DAPI-stained cover slips were inspected to exclude
the possibility of Mycoplasma contamination.
The quantitative analysis was performed using an image
analysis system (Image-ProH Plus 4.5, Media Cybernetics, Inc,
Silver Spring, MD, USA) composed of a digital camera (Evolution,
Media Cybernetics, Inc, Silver Spring, MD, USA) coupled to a
fluorescence microscope. High quality images of cells were
captured (204861536 pixels buffer), using the 406objective lens.
At least twenty fields per cover slip were counted and the
percentage of immunoreactive cells was calculated from the DAPI
positive cells.
The expression of Bax, Bcl-2, VEGF and survivin were also
assessed by western blot using specific antibodies. Plated cells were
treated with medium or 50 mg/mL OA for 24 h and whole cell
extracts were prepared as described in Expression of MDR proteins
(M&M). Proteins were separated by SDS-Page, transferred to PDF
membranes and probed with specific antibodies for Bax (clone P-
19, 1:1000), Bcl-2 (clone Bcl2-100, 1:500), VEGF (clone C1,
1:100), survivin (clone ab469, 1: 1000) or tubulin (clone b-7,
1:500). Blots were developed using the enhanced chemilumines-
cence system (ECL, Amersham, Arlington, IL) according to the
manufacturer’s instructions. Band intensity was quantified using
the Scion Image Software and protein expression was normalized
in relation to a-tubulin.
Development of lung metastasis induced by B16F10
melanoma cells
All animal experimental procedures were conducted in
accordance with the guidelines of the Ethics Committee for
Evaluation of Animal Use in Experimentation from the IBCCF/
CCS/UFRJ (CAUAP-IBCCF) and approved under the designa-
tion, Project # 1005.
On day 0, male C57BL/6 mice (10 to 12-weeks-old) were injected
into their tail veins with B16F10 melanoma cells (1610
6 cells/
animal). Tumor-cell-bearing mice were divided into four groups of
five and 3 days after inoculation, treated daily for two weeks (from
Monday to Friday) with 20 mL of saline, of DMSO or of OA
(5 mg kg
21 or 10 mg kg
21). The dose of the triterpene for the third
and fourth groups was decided by reference to a previous report [29].
The body weight of each mouse was recorded every 4 days to
determine whether the treatment influenced the animal’s health
status. Eighteen days after inoculation of the tumor cells, the mice
were killed by cervical dislocation under anesthesia with CO2.T h e
lungs were removed, and two independent observers determined the
Oleanolic Acid in Cancer
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28596number of metastatic nodules on the lungs of each mouse. Results are
expressed as mean 6 SD of the number of metastasis.
Statistical analysis
Data are presented as average 6 SD. Student’s t-test was
performed using Instat software. A value of p,0.05 was considered
statistically significant.
Results
A549 and H460 cell lines express active MRP1 pump
The A549 and H460 cell lines express significant levels of MDR
transporter proteins [25,26]. To investigate the presence of active
pumps in these lines, cells were incubated with fluorescence
substrates for P-gp (Rho123) or MRP1 (CFDA) in the presence or
absence of inhibitors for these proteins and then the intracellular
fluorescence was measured. The lack of alteration in fluorescence
observed in the presence of verapamil, a specific P-gp inhibitor
[30], and the high increase in fluorescence obtained when A549
and H460 were treated with MK571, a specific MRP1 inhibitor
[31], indicated that these lines have very low or no P-gp activity,
but display a strong MRP1 activity (Figure 1).
Oleanolic acid inhibits viability and induces caspase-
dependent DNA fragmentation in NSCLC lines
To evaluate the cytotoxic effect of OA on A549 and H460, cells
were treated with different concentrations of OA or with cisplatin
(a traditional chemotherapeutic drug for NSCLC) and then, 48 h
later; viability of the cells was measured by a MTT assay.
Oleanolic acid decreased the viability of the cell lines in a dose-
dependent manner (Figure 2A). Microscopic observation of the
cells suggested that the effect of OA was due to apoptosis. To
explore this observation further, treated cells were incubated with
a hypotonic solution containing PI and then a cell cycle analysis
was performed by flow cytometry (FCM). Sub-diploid populations
were considered apoptotic. The increased percentage of frag-
mented DNA cells and the activation of caspase-3 activity induced
by the OA treatment (Figures 2B and 2C), reinforced the apoptotic
nature of OA cytotoxicity. This observation was confirmed by
AnnexinV/PI data (data not shown).
Effects of oleanolic acid on MDR activity and expression
To investigate if the cytotoxic effect of OA on A549 and H460
was mediated by modulation of the MDR pump, we analyzed the
effects of OA on MRP1 activity and expression. Cells were
incubated for 30 min with CFDA in the presence of different OA
concentrations (6.25, 12.5, 25 or 50 mg/mL) and the accumulation
of CF was measured by fluorescence. As shown in Figure 3A,
treatment with OA did not alter the accumulation of CF by A549.
A small but significant increase in fluorescence was observed in
H460, suggesting that OA may be able to modulate MRP1
activity. On the other hand it was also possible, instead, that OA
modifies the expression of MRP1. This possibility was analyzed by
FCM and western blot in cells incubated with medium or OA (25
or 50 mg/mL, each for 24 hours and then treated with anti-
MRP1. As shown in Figures 3B and 3C, no alteration of MRP1
expression was observed.
Oleanolic acid inhibits the expression of proteins
involved in resisting apoptosis and inducing
angiogenesis on the A549 cell line
To investigate if the cytotoxic activity of OA could be due to
modulation of pathways involved in apoptosis resistance, A549
cells were treated for 24 h with 50 mg/mL of this triterpene and
then the expression of Bcl-2, Bax and survivin were analyzed using
immunocytochemical techniques. We found no mycoplasma in
cover slips prepared for immunocytochemistry. We observed that
the expression of Bcl-2 did not change after treatment with OA
(Figures 4A–B); there was a significant (p,0.005) increase in Bax
(Figures 4C–D) and a significant decrease (p,0.0001) in
expression of survivin protein (Figures 4E–F). These results
suggested that treatment with OA altered the cellular milieu
towards an apoptotic profile and that this process may also
contribute to reducing the number of metastatic foci. To explore
this possibility further, the effect of OA on the expression of VEGF
[13], a factor involved in cell proliferation and angiogenesis, was
evaluated by immunocytochemistry. Data presented in Figures 4
(G–H) showed that treatment with OA led to a significant
reduction (p,0.05) of VEGF-positive cells. Similar results were
observed when the effects of OA on the expression of these
proteins were analyzed by western blot (Figure 5). Altogether,
these data reinforce a possible inhibitory effect of OA on drug
resistance pathways and development of metastasis.
Figure 1. Non-small cell lung cancer cell lines express MRP1/
ABCC1 activity. For P-gp/ABCB1 activity, A549 or H460 cells were
incubated for 30 min with medium (AF) or 400 nM Rhodamine 123 in
the absence (Rho) or presence of 50 mM verapamil (VP), For MRP1/
ABCC1, cells were incubated with 5 mM CFDA in the absence (CF) or
presence of 50 mM MK-571 (MK). After washing, cellular fluorescence
was measured by flow cytometry. Histograms are representative of
three independent experiments performed in duplicate.
doi:10.1371/journal.pone.0028596.g001
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28596Figure 2. Oleanolic acid (OA) decreases cell viability and induces apoptosis of non-small cell lung cancer cell lines. A549 or H460 cells
were incubated with various OA concentrations (10, 25, 40 or 50 mg/mL or 21.9, 54.7, 87.6 or 109.5 mM) or cisplatin for 48 h. (A) Cell viability was
assessed by MTT and plotted as percentage of cell viability inhibition. Results represent mean 6 SD of 4 experiments performed in triplicate. (B)I n
parallel, cells were treated with a hypotonic solution containing propidium iodide (PI) and DNA-content was analyzed by flow cytometry. Upper
panel: representative histogram of the cell cycle. Lower panel: percentage of apoptotic sub-G1 cells. Values represent mean 6 SD of 3 experiments
performed in triplicate. (C) Caspase-3 activated cells was determined by flow cytometry using a CaspGlow kit as described in M&M. Histograms are
representative of two independent experiments performed in duplicate.
doi:10.1371/journal.pone.0028596.g002
Figure 3. Effect of Oleanolic acid on MRP1/ABCC1 activity and expression. (A) To determine MRP1 activity, A549 or H460 cells were
incubated for 30 min with medium (AF), 5 mM CFDA in the absence (CF) or presence of 50 mM MK-571 (MK-571), or with CFDA in the presence of
various concentrations of OA (6.25, 12.5, 25 or 50 mg/mL). Cellular fluorescence was measured by flow cytometry. Results are expressed as the mean
6 S.D of the mean fluorescence intensity obtained in 3 different experiments performed in triplicate. * and ** indicate p,0.05 and p,0.01
respectively, in relation to the control (CF). (B) To determine MRP1 expression, cells were treated with medium or OA (25 or 50 mg/mL) for 24 h before
being harvested, permeabilized and incubated with PE-labeled anti-MRP1 for 30 minutes at 4uC. After two PBS washings, the cells were re-suspended
in FACS solution and the fluorescence was evaluated. Histograms are representative of three independent experiments. (C) To determine MRP1 by
western blot, whole-cell extracts were obtained from cells treated as described in B. Proteins were separated by sodium dodecyl sulphate (SDS)-gels,
transferred to PDF membranes and probed with an antibody to MRP1 as described in the M&M section. Numbers represent band intensity in relation
to a-tubulin.
doi:10.1371/journal.pone.0028596.g003
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induced lung metastasis
Metastasis is generally considered a tumor growth originated
from cells that lost adherence, entered the circulation, and then
migrated to specific metastatic niches; in the case of lung cancer,
these niches are the brain, liver and bones. In the absence of a
model for metastasis specific for this particular type of lung cancer,
we employed the melanoma model, frequently used in the
literature to investigate the effect of drugs on metastasis, to access
the effects of OA on the development of metastasis in vivo. For this
purpose, lung metastases were induced by i.v. inoculation of
B16F10 melanoma cells as previously described [29]. In a manner
Figure 4. Effect of Oleanolic acid (OA) on proteins involved on apoptotic and metastatic pathways. (Upper panel)
Immunofluorescence of A549 cells stained for Bcl2 (A–B), Bax (C–D), survivin (E–F) and VEGF (G–H). A549 cells were treated with medium
(A,C,E,G) or with 50 mg/mL OA (B, D, F, H) for 24 h, fixed, stained with the primary antibodies, revealed with biotinilated IgG followed by streptavidin-
Cy3 and counter stained with DAPI, as described in M&M. Representative immunofluorescence micrographs of three experiments. Bar: 100 mm.
(Lower panel) Graphical representation of the histomorphometrical results of the immunocytochemical assay. The percentage of immunoreactive
cells was calculated from the DAPI positive cells. Bcl-2 was not modulated by OA (p.0.05), but Bax was significantly increased (* p,0.005), while
survivin and VEGF were significantly decreased after treatment (**p,0.0001 and ***p,0.05, respectively).
doi:10.1371/journal.pone.0028596.g004
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pump (results not shown). Starting 3 days after tumor inoculation,
groups of mice were treated intra-nasally for 2 weeks with 10 doses
of PBS (control) or various concentrations of OA (5 or 10 mg kg
21
day
21). The mice were sacrificed at day 17 and the number of
pulmonary metastasis was counted. The higher concentration
treatment with OA significantly (p,0.05) reduced the number of
metastasis as compared to non-treated controls (Figure 6).
Discussion
The presence of intrinsic or acquired resistance to chemother-
apeutic agents is a major obstacle to the effective treatment of
NSCLC. Indeed, the observation that about half of the patients die
because the tumor spreads to distant organs has been attributed to
the development of MDR. Data presented here demonstrated
that, in addition to being active against NSCLC lines that
expressed intrinsic MRP1/ABCC1 activity, OA modulated factors
involved in apoptosis resistance and inhibited the development of
melanoma-induced lung metastasis.
Because MDR proteins are found in the normal lung
epithelium, tumors derived from this tissue raise levels of these
proteins following chemotherapy or radiotherapy [32,33] and are
often insensitive to cytotoxic agents. Data presented in this paper
demonstrated that OA is cytotoxic and induced apoptosis of two
NSCLC cells that constitutively express MRP1 [25,26] and
present high MRP1 activity (Figure 1). Oleanolic acid-mediated
cell death is due to apoptosis, as evidenced by OA’s capacity to
induce fragmentation of DNA and to activate caspase 3 (Figure 2).
Although results obtained with H460 suggested that OA had a
modulating effect on MRP1, no modulation was seen in A549
(Figure 3A). This difference is probably due to the presence of
other members of the ABCC1 family of transporters in this cell
line. In fact, A549 was shown to express MRP1-5 [25] and the
transport properties of MRP3 and its involvement in resistance of
lung cancer have been proposed [34].
Previous data from our group indicated that OA may modulate
MRP1/ABCC1 activity [35]. It is important to note that despite
its slight modulatory effect on MRP1/ABCC1 activity, OA did not
induce an increase in the expression of MRP1 (Figures 3B and
3C). MRP1 is a non-selective ATP-dependent pump capable of
transporting several physiological and non-physiological substrates
including anticancer drugs [6]. As our group recently proposed,
the capacity of OA to bypass MRP1 may be due to its physical-
chemical properties, since compounds with low polar surface area
such as OA are not transported by MRP1 [36]. Results showing
that OA kills cells that display high MRP1/ABCC1 activity
(Fig. 2) suggest that OA is not a substrate for this protein.
In NSCLC, drug resistance has also been associated with altered
expression of anti-apoptotic members of the Bcl-2 [37] and the
IAPs families [38]. Treatment with OA increased the expression of
Bax without altering Bcl-2 (Figs 4A–D and Fig. 5), leading to a
pro-apoptotic balance of these proteins in the cell. It also reduced
the expression of survivin (Figs. 4E, 4F and 5), a structurally
unique member of the IAP family that plays a central role in cell
division and acts as a suppressor of apoptosis [39]. These data
suggested that OA-induced apoptosis of NSCLC may be due to a
down-modulation effect of the anti-apoptotic factors present in the
cell.
Increasing evidence suggests that lung cancer uses multiple and
redundant pathways to maintain tumor survival and development.
The results presented here showed that the ability of OA to control
tumor growth is probably due to its capacity to interfere with
different resistance pathways present in the cell. Thus, OA not
only contributed to cell death by down-modulating anti-apoptotic
factors, but it inhibited tumor cell proliferation. Since disseminated
tumor cells have been found in a dormant state for prolonged
periods of time [40], targeting these cells and preventing their
outgrowth could be a promising approach to interfering with
metastasis.
Figure 5. Western blot analysis. A549 cells were treated with
medium or with 50 mg/mL Oleanolic acid for 24 h and whole cell
extracts were obtained as described in M&M. Proteins were separated
by SDS-PAGE, transferred to PDF membranes, probed with antibodies
to Bcl-2, Bax, Survivin, VEGF or a-tubulin and developed with ECL, as
described in M&M. Numbers represent band intensity in relation to a-
tubulin.
doi:10.1371/journal.pone.0028596.g005
Figure 6. Oleanolic acid (OA) inhibits the development of lung
metastasis. Groups of mice, injected into the tail veins with B16F10
melanoma cells, were treated with saline, DMSO, OA (5 mg kg
21 day
21)
or OA (10 mg kg
21 day
21), as described in the M&M section and in the
upper panel; the number of lung metastasis was counted on day 18
(lower panel). Results are expressed as mean 6 SD of the number of
metastasis. * indicates p,0.001 in relation to the control (DMSO).
doi:10.1371/journal.pone.0028596.g006
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relapse following systemic treatments is often associated with
resistance that might be due to the cancer cell’s intrinsic
mechanisms, such as genetic alterations leading to expression of
MDR proteins or anti-apoptotic factors [14,41]. Treatment with
OA not only bypasses these mechanisms but also significantly
reduces the development of pulmonary metastasis induced by
inoculation of mice with B16F10, a cell lineage that presented high
MRP1 activity (data not shown) and other resistance mechanisms
[42].
Drug resistance is a severe limitation on chemotherapy of
various malignancies. Advanced lung cancer is a multifactorial
disease that demands treatments targeting multiple cellular
pathways. The search for new drugs able to overcome cancer’s
resistance mechanisms and to prevent the development of the
metastasis favored by this disease, is of great interest for lung
cancer therapy. Chemotherapy based on Cisplatin, one of the
main drugs used to treat lung cancer, seemed to have reached a
dead-end regarding malignant lung cancer, leading clinical
researchers to evaluate the validity of continuing its use in
advanced lung cancer patients.
Prolongation of survival, reduced toxicity and improved quality
of life are currently the main objectives of advanced NSCLC
treatment. However, because side effects were also observed in the
chemotherapeutic regimens incorporating new second and third
generation drugs and target-directed agents, reducing side effects
may be considered an improvement over the current state of the
art for lung cancer chemotherapy. In this context, OA produced
its benefits without showing any hepato- or nephro-toxicity in
experimental models [18,19] and furthered the reconstitution of
bone marrow after irradiation [43]. In addition, short and long
term clinical trials using OA for acute and chronic hepatitis,
respectively, demonstrated the safety of this compound [44].
The results presented in this paper showed that, in addition to
killing cells expressing different drug resistance mechanisms, OA
also attenuates the development of pulmonary metastasis. Taken
together, these results indicate the potential of this compound as a
chemotherapeutic agent or as a co-adjuvant for the treatment of
resistant tumors such as lung tumors.
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